|
Mechanism50S subunit inhibitors [+4] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date01 Nov 2019 |
100 Clinical Results associated with Talicia Holdings, Inc.
0 Patents (Medical) associated with Talicia Holdings, Inc.
100 Deals associated with Talicia Holdings, Inc.
100 Translational Medicine associated with Talicia Holdings, Inc.